Results 21 to 30 of about 5,550 (180)

JAK2 V617F constitutive activation requires JH2 residue F595: a pseudokinase domain target for specific inhibitors. [PDF]

PLoS ONE, 2010
The JAK2 V617F mutation present in over 95% of Polycythemia Vera patients and in 50% of Essential Thrombocythemia and Primary Myelofibrosis patients renders the kinase constitutively active.
Alexandra Dusa, Céline Mouton, Christian Pecquet, Murielle Herman, Stefan N Constantinescu   +4 more
doaj   +1 more source

Superiority of Droplet Digital PCR Over Real-Time Quantitative PCR for JAK2 V617F Allele Mutational Burden Assessment in Myeloproliferative Neoplasms: A Retrospective Study

Diagnostics, 2020
JAK2 V617F mutational status is an essential diagnostic index in myeloproliferative neoplasms (MPNs). Although widely used for detection of JAK2 V617F mutation in peripheral blood (PB), sensitive real-time quantitative PCR (qPCR) presents some ...
Francesco La Rocca, Vitina Grieco, Vitalba Ruggieri, Emanuela Zifarone, Oreste Villani, Pietro Zoppoli, Sabino Russi, Simona Laurino, Geppino Falco, Giovanni Calice, Anna Marinaccio, Maria Iole Natalicchio, Francesco Albano, Pellegrino Musto   +13 more
doaj   +1 more source

Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F. [PDF]

PLoS ONE, 2006
A somatic activating mutation (V617F) in the JAK2 tyrosine kinase was recently discovered in the majority of patients with polycythemia vera (PV), and some with essential thrombocythemia (ET) and chronic idiopathic myelofibrosis.
Virginia M Zaleskas, Daniela S Krause, Katherine Lazarides, Nihal Patel, Yiguo Hu, Shaoguang Li, Richard A Van Etten   +6 more
doaj   +1 more source

JAK2 (V617F) mutation in healthy individuals

British Journal of Haematology, 2007
n ...
PASSAMONTI, FRANCESCO, Rumi E, Pietra D, Lazzarino M, Cazzola M.   +4 more
openaire   +5 more sources

JAK2 V617F Mutation in Adult Taiwanese Patients with Essential Thrombocythemia: More Prevalent in Old Patients and Correlated with Higher Hemoglobin Level and Higher Leukocyte Count

International Journal of Gerontology, 2013
Background: Essential thrombocythemia (ET) is classified as a chronic myeloproliferative neoplasm. JAK2 V617F mutation is found in about 50–60% patients with ET. We aim to determine the prevalence of JAK2 V617F mutation and its association with phenotype
Huan-Chau Lin, Caleb Gon-Shen Chen, Ming-Chih Chang, Wei-Ting Wang, Chen Wei Kao, An-Chi Lo, Nai-Wen Su, Yu-Cheng Chang, Yi-Hao Chiang, Kuei-Fang Chou, Po-Nien Liao, Guan-Jhe Cai, Hung-I Cheng, Johnson Lin, Yi-Fang Chang, Ruey-Kuen Hsieh, Ken-Hong Lim   +16 more
doaj   +1 more source

JAK2 V617F Analysis in Indonesian Myeloproliferative Neoplasms Patients

Journal of Biomedicine and Translational Research, 2015
Background : Three subtypes of myeloproliferative neoplasms (MPNs): Polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) showed overlapping phenotype.
Fanti Saktini, Santosa Santosa, Sultana MH Faradz   +2 more
doaj   +1 more source

Somatic mutation of the V617F JAK2 gene in patients of the cardiovascular diseases

Терапевтический архив, 2019
The JAK2 V617F somatic mutation is one of the most frequent markers of CHIP (clonal hematopoiesis of indeterminate potential). CHIP is characterized by the presence of a myeloid cells clone in peripheral blood in the absence of the sufficient reasons to ...
I A Olkhovskiy, A S Gorbenko, M A Stolyar, D A Grischenko, O A Tkachenko, T L Martsinkevich   +5 more
doaj   +1 more source

Allelic expression imbalance of JAK2 V617F mutation in BCR-ABL negative myeloproliferative neoplasms. [PDF]

PLoS ONE, 2013
The discovery of a single point mutation in the JAK2 gene in patients with BCR/ABL-negative myeloproliferative neoplasms (MPNs) has not only brought new insights and pathogenesis, but also has made the diagnosis of MPNs much easier.
Hye-Ran Kim, Hyun-Jung Choi, Yeo-Kyeoung Kim, Hyeoung-Joon Kim, Jong-Hee Shin, Soon-Pal Suh, Dong-Wook Ryang, Myung-Geun Shin   +7 more
doaj   +1 more source

The JAK2 V617F mutation in patients with cerebral venous thrombosis [PDF]

Journal of Thrombosis and Haemostasis, 2012
It is currently unclear whether or not cerebral venous thrombosis, such as splanchnic venous thrombosis, can be the first manifestation of an underlying myeloproliferative neoplasm.To determine the prevalence of the JAK2 V617F mutation in patients with a first episode of cerebral venous thrombosis.In this retrospective cohort study, patients with ...
Passamonti SM, Biguzzi E, Franchi F, Gianniello F, Bucciarelli P, Pietra D, Mannucci PM, Martinelli I., CAZZOLA, MARIO   +8 more
openaire   +3 more sources

Is the JAK2^V617F mutation detectable in healthy volunteers? [PDF]

American Journal of Hematology, 2010
The World Health Organization (WHO) has added detection of the JAK2 tyrosine kinase mutation, JAK2 V617F, in the diagnostic work up for myeloproliferative neoplasms (MPNs), especially for polycythemia vera (PV) and essential thrombocythemia (ET).
Christophe, Martinaud, Patrick, Brisou, Marie-Joelle, Mozziconacci   +2 more
openaire   +2 more sources